Three‐dimensional model of the cyclin‐dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKS

Cyclin‐dependent kinase 1 (CDK1) is an interesting target for potential anticancer drugs, and its three‐dimensional (3D) structure is presently unknown. The purpose of this work was to build a 3D model of CDK1, which could be used in drug design studies. The protein 3D structure was homology modeled, based on the known crystal structure of CDK2, and new nonbonded parameters for the Mg2+ coordination complex were developed by means of ab initio quantum chemical calculations. These parameters were both obtained and validated using the CDK2 structure as reference, and then they were used for the refinement of the CDK1 model. The resulting CDK1 structure was satisfactory and stable at room temperature, as shown by the molecular dynamics simulations carried out over a 1‐ns time interval on the entire protein. A number of representative kinases in the active and inactive form, including the inactive CDK1 modeled in this work, were compared. The results illustrate the conformational variability of the activation loop of the inactive form of the kinases and suggest a way for selectively targeting the single CDKs. Proteins 2001;45:478–485. © 2001 Wiley‐Liss, Inc.

[1]  Philip R. Cohen,et al.  The development and therapeutic potential of protein kinase inhibitors. , 1999, Current opinion in chemical biology.

[2]  M. Morris,et al.  Kinetics of dimerization and interactions of p13suc1 with cyclin-dependent kinases. , 1998, Biochemistry.

[3]  D. Fesquet,et al.  Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism. , 1997, Biochemistry.

[4]  L. Toledo,et al.  The structure-based design of ATP-site directed protein kinase inhibitors. , 1999, Current medicinal chemistry.

[5]  B. Honig,et al.  Classical electrostatics in biology and chemistry. , 1995, Science.

[6]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[7]  G L Trainor,et al.  Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.

[8]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[9]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[10]  P A Kollman,et al.  Molecular dynamics characterization of the active cavity of carboxypeptidase A and some of its inhibitor adducts , 1992, Proteins.

[11]  G. Folkers,et al.  Compulsory Order of Substrate Binding to Herpes Simplex Virus Type 1 Thymidine Kinase , 2000, The Journal of Biological Chemistry.

[12]  Mingjie Zhang,et al.  Cyclin-dependent Kinase 5 (Cdk5) Activation Domain of Neuronal Cdk5 Activator , 1997, The Journal of Biological Chemistry.

[13]  J. Endicott,et al.  Cyclin-dependent kinases: inhibition and substrate recognition. , 1999, Current opinion in structural biology.

[14]  L. Johnson,et al.  Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.

[15]  L Meijer,et al.  Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. , 2000, Anti-cancer drug design.

[16]  G Folkers,et al.  The effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinase , 2001, Protein science : a publication of the Protein Society.

[17]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[18]  P. Furet,et al.  Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. , 2000, Biochemical and biophysical research communications.

[19]  L. Meijer,et al.  Chemical inhibitors of cyclin-dependent kinases , 1997 .

[20]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[21]  E. de Moliner,et al.  The Replacement of ATP by the Competitive Inhibitor Emodin Induces Conformational Modifications in the Catalytic Site of Protein Kinase CK2* , 2000, The Journal of Biological Chemistry.

[22]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[23]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[24]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[25]  Peter A. Kollman,et al.  Advancing beyond the atom-centered model in additive and nonadditive molecular mechanics , 1997, Journal of Computational Chemistry.

[26]  L. Meijer,et al.  ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.

[27]  A H Calvert,et al.  Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. , 2000, Journal of medicinal chemistry.

[28]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[29]  G. Schulz,et al.  Movie of the structural changes during a catalytic cycle of nucleoside monophosphate kinases. , 1995, Structure.

[30]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[31]  J. Koča,et al.  Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. , 2000, Journal of medicinal chemistry.

[32]  Mingjie Zhang,et al.  Cyclin-dependent Kinase 5 ( Cdk 5 ) Activation Domain of Neuronal Cdk 5 Activator EVIDENCE OF THE EXISTENCE OF CYCLIN FOLD IN NEURONAL Cdk 5 a ACTIVATOR , 1997 .

[33]  L. Itzhaki,et al.  Stability and folding of the cell cycle regulatory protein, p13(suc1). , 1998, Journal of molecular biology.

[34]  L. Johnson,et al.  Active and Inactive Protein Kinases: Structural Basis for Regulation , 1996, Cell.